Product details

This case tells the spectacular story of how a new management team turned around Celltech from near collapse in 1990 to one of the largest bio-pharmaceutical firms in Europe by the late 1990s. Initially through the lens of a single critical drug discovery and development project the case explains how Celltech moved away from low margin contract manufacturing to high risk, high return, drug R&D. It shows how Celltech carefully managed both the process of renewal and management of risk via alliances with leading pharmaceutical firms. The events of the case are particularly relevant as this strategy formed the foundations of the firm''s rapid growth in the late 1990s and entry (post case) into the FTSE 100 index in 2000. The accompanying teaching note offers six student assignments, detailed analysis of each question, and eight suggested readings to choose from. An accompanying note on the biotechnology industry is also available (300-071-6).